IL-2 and Melatonin in Advanced Solid Tumors
Author Information
Author(s): P. Lissonil, S. Barnil, G. Tancinil, A. Ardizzoial, G. Ricci, R. Aldeghi, F. Brivio, E. Tisi, F. Rovelli, R. Rescaldani, G. Quadro, G. Maestroni
Primary Institution: San Gerardo Hospital, Monza, Milan, Italy
Hypothesis
Can the combination of interleukin 2 and melatonin improve treatment outcomes in advanced solid tumors?
Conclusion
The study shows that combining melatonin with low-dose interleukin 2 significantly increases tumor regression rates and overall survival in patients with advanced solid tumors.
Supporting Evidence
- 3 out of 41 patients treated with IL-2 plus melatonin achieved a complete response.
- 8 out of 41 patients treated with IL-2 plus melatonin achieved a partial response.
- The objective tumor regression rate was significantly higher in patients treated with IL-2 and melatonin compared to those receiving IL-2 alone.
- Survival at 1 year was significantly higher in patients treated with IL-2 and melatonin than in the IL-2 group.
Takeaway
This study found that giving a hormone called melatonin along with a treatment called interleukin 2 helps more people with serious tumors get better.
Methodology
80 patients with advanced solid tumors were randomized to receive either low-dose IL-2 alone or IL-2 plus melatonin, with responses evaluated after treatment.
Limitations
The study did not include patients with brain metastases or those receiving long-term steroid therapy.
Participant Demographics
{"gender_ratio":"M/F 43/37","median_age":55,"performance_status":"60 (Karnofsky's score)"}
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website